GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699 · see citing works

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429 · see citing works

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · see citing works

Hepatocellular carcinoma

Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055 · see citing works

Role for a bidentate ribonuclease in the initiation step of RNA interference

Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001) · Nature · doi:10.1038/35053110 · Cited by 4,896 · see citing works

A global view of hepatocellular carcinoma: trends, risk, prevention and management

Yang, J. D., Hainaut, P. L., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,233 · see citing works

Mechanisms of gene silencing by double-stranded RNA

Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539 · see citing works

A comprehensive map of molecular drug targets

Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427 · see citing works

Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus

Yan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., Huang, Y., Qi, Y., Peng, X., Wang, H., et al. (2012) · eLife · doi:10.7554/elife.00049 · Cited by 2,121 · see citing works

Delivery materials for siRNA therapeutics

Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800 · see citing works

Therapeutic siRNA: state of the art

Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586 · see citing works

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555 · see citing works

Hepatitis B Virus Biology

Seeger, C., & Mason, W. S. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.1.51-68.2000 · Cited by 1,457 · see citing works

The liver

Trefts, E., Gannon, M., & Wasserman, D. H. (2017) · Current Biology · doi:10.1016/j.cub.2017.09.019 · Cited by 1,452 · see citing works

Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate

Elbashir, S. M., Martinez, J., Patkaniowska, A., Lendeckel, W., & Tuschl, T. (2001) · The EMBO Journal · doi:10.1093/emboj/20.23.6877 · Cited by 1,449 · see citing works

Nonalcoholic Steatohepatitis

Sheka, A. C., Adeyi, O. A., Thompson, J., Hameed, B., Crawford, P. A., & Ikramuddin, S. (2020) · JAMA · doi:10.1001/jama.2020.2298 · Cited by 1,398 · see citing works

Drug delivery systems for RNA therapeutics

Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349 · see citing works

Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms

Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261 · see citing works

The chemical evolution of oligonucleotide therapies of clinical utility

Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216 · see citing works

Multivalent <i>N</i> -Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing

Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141 · see citing works

Overcoming cellular barriers for RNA therapeutics

Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139 · see citing works

par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed

Guo, S., & Kemphues, K. J. (1995) · Cell · doi:10.1016/0092-8674(95)90082-9 · Cited by 1,113 · see citing works

Immune Responses in the Liver

Kubes, P., & Jenne, C. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052415 · Cited by 923 · see citing works

Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection

Boni, C., Fisicaro, P., Valdatta, C., Amadei, B., Di Vincenzo, P., Giuberti, T., Laccabue, D., Zerbini, A., Cavalli, A., Missale, G., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02844-06 · Cited by 920 · see citing works

HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B

Nassal, M. (2015) · Gut · doi:10.1136/gutjnl-2015-309809 · Cited by 906 · see citing works

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆

Werle–Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G., Trepo, C., Marcellin, P., Goodman, Z., & Delaney IV, W. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.018 · Cited by 905 · see citing works

Chemistry of Lipid Nanoparticles for RNA Delivery

Eygeris, Y., Gupta, M., Kim, J., & Sahay, G. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00544 · Cited by 903 · see citing works

Molecular biology of hepatitis B virus infection

Seeger, C., & Mason, W. S. (2015) · Virology · doi:10.1016/j.virol.2015.02.031 · Cited by 868 · see citing works

Targeted mRNA degradation by double-stranded RNA in vitroPreprint

Tuschl, T., Zamore, P. D., Lehmann, R., Bartel, D. P., & Sharp, P. A. (1999) · Genes & Development · doi:10.1101/gad.13.24.3191 · Cited by 843 · see citing works

RNA-Targeted Therapeutics

Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841 · see citing works

A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates

Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.010 · Cited by 820 · see citing works

The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage

Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721 · see citing works

GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics

Springer, A. D., & Dowdy, S. F. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0736 · Cited by 711 · see citing works

Progress towards in Vivo Use of siRNAs

Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677 · see citing works

Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis

Schwabe, R. F., Tabas, I., & Pajvani, U. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.311 · Cited by 671 · see citing works

Lipids and Lipid Derivatives for RNA Delivery

Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 638 · see citing works

Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applications

D’souza, A. A., & Devarajan, P. V. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.022 · Cited by 624 · see citing works

Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells

Scacheri, P. C., Rozenblatt–Rosen, O., Caplen, N. J., Wolfsberg, T. G., Umayam, L. A., Lee, J. C., Hughes, C. M., Shanmugam, K. S., Bhattacharjee, A., Meyerson, M. M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308698100 · Cited by 613 · see citing works

Accelerated Blood Clearance and Altered Biodistribution of Repeated Injections of Sterically Stabilized Liposomes

Dams, E. T. M., Laverman, P., Oyen, W. J. G., Storm, G., Scherphof, G. L., van der Meer, J. W. M., Corstens, F. H. M., & Boerman, O. C. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35391-1 · Cited by 606 · see citing works

Lipid nanoparticles enabling gene therapies: from concepts to clinical utility

Kulkarni, J. A., Cullis, P. R., & van der Meel, R. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0721 · Cited by 592 · see citing works

In vivo activity of nuclease-resistant siRNAs

Layzer, J. M., McCaffrey, A. P., Tanner, A. K., Huang, Z., Kay, M. A., & Sullenger, B. A. (2004) · RNA · doi:10.1261/rna.5239604 · Cited by 581 · see citing works

Strategies, design, and chemistry in siRNA delivery systems

Dong, Y., Siegwart, D. J., & Anderson, D. G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.004 · Cited by 581 · see citing works

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

Fitzgerald, K. J., Frank-Kamenetsky, M. D., Shulga‐Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J. E., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 574 · see citing works

Chronic hepatitis B virus infection

Seto, W., Lo, Y.-R. J., Pawlotsky, J., & Yuen, M. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31865-8 · Cited by 560 · see citing works

Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs

Lokugamage, M. P., Vanover, D. A., Beyersdorf, J. P., Hatit, M. Z. C., Rotolo, L., Echeverri, E. S., Peck, H. E., Ni, H., Yoon, J., Kim, Y., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00786-x · Cited by 509 · see citing works

Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin. Dependence on fine structural features.

Lee, Y. C., Townsend, R. R., Hardy, M. R., Lönngren, J., Arnarp, J., Haraldsson, M., & Lönn, H. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)33240-x · Cited by 503 · see citing works

Adaptive immunity in HBV infection.

Bertoletti, A., & Ferrari, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.026 · Cited by 461 · see citing works

Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells

Filion, M. C., & Phillips, N. C. (1997) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(97)00126-0 · Cited by 428 · see citing works

Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes

Wang, X., Ishida, T., & Kiwada, H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.02.010 · Cited by 421 · see citing works

Therapeutic siRNA: State-of-the-Art and Future Perspectives

Friedrich, M., & Aigner, A. M. (2022) · BioDrugs · doi:10.1007/s40259-022-00549-3 · Cited by 413 · see citing works

Hepatitis B virus biology and life cycle

Tsukuda, S., & Watashi, K. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104925 · Cited by 388 · see citing works

Hepatitis B viruses: Reverse transcription a different way

Nassal, M. (2008) · Virus Research · doi:10.1016/j.virusres.2007.12.024 · Cited by 381 · see citing works

Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡

Cornberg, M., Lok, A. S.-F., Terrault, N. A., Zoulim, F., Berg, T., Brunetto, M. R., Buchholz, S., Buti, M., Chan, H. L., Chang, K., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.003 · Cited by 368 · see citing works

The Binding of Desialylated Glycoproteins by Plasma Membranes of Rat Liver

Pricer, W. E., & Ashwell, G. (1971) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)62010-1 · Cited by 362 · see citing works

Nucleic acid delivery for therapeutic applications

Gupta, A., Andresen, J. L., Manan, R. S., & Langer, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113834 · Cited by 339 · see citing works

Non-viral vectors for RNA delivery

Yan, Y., Liu, X.-Y., Lu, A., Wang, X.-Y., Jiang, L.-X., & Wang, J.-C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.008 · Cited by 332 · see citing works

Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates

Foster, D. J., Brown, C. R., Shaikh, S., Trapp, C., Schlegel, M. K., Qian, K., Sehgal, A., Rajeev, K. G., Jadhav, V., Manoharan, M., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.021 · Cited by 325 · see citing works

An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia

Sehgal, A., Barros, S. A., Ivanciu, L., Cooley, B. C., Qin, J., Racie, T., Hettinger, J. L., Carioto, M., Jiang, Y., Brodsky, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3847 · Cited by 307 · see citing works

Hepatitis B virus morphogenesis

Bruss, V. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i1.65 · Cited by 288 · see citing works

Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Spengler, E. K., & Loomba, R. S. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.06.013 · Cited by 285 · see citing works

Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates

Brown, C. R., Gupta, S., Qin, J., Racie, T., He, G., Lentini, S., Malone, R., Yu, M., Matsuda, S., Shulga-Morskaya, S., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa670 · Cited by 285 · see citing works

Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics

Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V., & Winkler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.003 · Cited by 284 · see citing works

Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates

Nair, J. K., Attarwala, H., Sehgal, A., Wang, Q., Aluri, K., Zhang, X., Gao, M., Liu, J., Indrakanti, R., Schofield, S., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx818 · Cited by 278 · see citing works

Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria

Hopp, K., Cogal, A. G., Bergstralh, E. J., Seide, B. M., Olson, J. B., Meek, A. M., Lieske, J. C., Milliner, D. S., & Harris, P. C. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070698 · Cited by 267 · see citing works

The response of mammalian cells to double-stranded RNA

Gantier, M. P., & Williams, B. R. G. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.06.016 · Cited by 266 · see citing works

Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs

Castaño, A., Drachman, B. M., Judge, D. P., & Maurer, M. S. (2014) · Heart Failure Reviews · doi:10.1007/s10741-014-9462-7 · Cited by 254 · see citing works

Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis

Zhu, C., Kim, K., Wang, X., Bartolome, A., Salomao, M., Dongiovanni, P., Meroni, M., Graham, M. J., Yates, K. P., Diehl, A. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat0344 · Cited by 250 · see citing works

Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization

Iwamoto, M., Saso, W., Sugiyama, R., Ishii, K., Ohki, M., Nagamori, S., Suzuki, R., Aizaki, H., Ryo, A., Yun, J.-H., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811064116 · Cited by 244 · see citing works

Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines

Aldosari, B. N., Alfagih, I. M., & Almurshedi, A. S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020206 · Cited by 242 · see citing works

Comparison of Cell Proliferation and Toxicity Assays Using Two Cationic Liposomes

Lappalainen, K., Jääskeläinen, I., Syrjänen, K. J., Urtti, A. O., & Syrjänen, S. (1994) · Pharmaceutical Research · doi:10.1023/a:1018932714745 · Cited by 238 · see citing works

Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach

Chalbatani, G. M., Dana, H., Gharagouzloo, E., Grijalvo, S., Eritja, R., Logsdon, C. D., Memari, F., Miri, S. R., Rad, M. R., & Marmari, V. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200253 · Cited by 238 · see citing works

Binding and endocytosis of cluster glycosides by rabbit hepatocytes. Evidence for a short-circuit pathway that does not lead to degradation.

Connolly, D. T., Townsend, R. R., Kawaguchi, K., Bell, W. R., & Lee, Y. C. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68290-6 · Cited by 224 · see citing works

siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes

Matsuda, S., Keiser, K., Nair, J. K., Charissé, K., Manoharan, R. M., Kretschmer, P., Peng, C. G., Kel’in, A. V., Pachamuthu, K., Willoughby, J. L. S., et al. (2015) · ACS Chemical Biology · doi:10.1021/cb501028c · Cited by 222 · see citing works

Current issues of RNAi therapeutics delivery and development

Haussecker, D. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.056 · Cited by 217 · see citing works

Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate

Zimmermann, T. S., Karsten, V., Chan, A., Chiesa, J., Boyce, M. J., Bettencourt, B. R., Hutabarat, R. M., Nochur, S. V., Vaishnaw, A. K., & Gollob, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.019 · Cited by 216 · see citing works

Next-Generation Lipids in RNA Interference Therapeutics

Rietwyk, S., & Peer, D. (2017) · ACS Nano · doi:10.1021/acsnano.7b04734 · Cited by 199 · see citing works

Molecular Virology of Hepatitis B Virus for Clinicians

Block, T. M., Guo, H., & Guo, J. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.08.002 · Cited by 189 · see citing works

New synthetic cluster ligands for galactose/N-acetylgalactosamine-specific lectin of mammalian liver

Lee, R. T., Lin, P., & Lee, Y. C. (1984) · Biochemistry · doi:10.1021/bi00313a037 · Cited by 180 · see citing works

Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development

Tout, I., Loureiro, D., Mansouri, A., Soumelis, V., Boyer, N., & Asselah, T. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.013 · Cited by 166 · see citing works

One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA

Zhang, D., Atochina‐Vasserman, E. N., Maurya, D. S., Huang, N., Xiao, Q., Ona, N. A., Liu, M., Shahnawaz, H., Ni, H., Kim, K., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c05813 · Cited by 163 · see citing works

Vutrisiran: First Approval

Keam, S. J. (2022) · Drugs · doi:10.1007/s40265-022-01765-5 · Cited by 154 · see citing works

Hepadnavirus Genome Replication and PersistencePreprint

Hu, J., & Seeger, C. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021386 · Cited by 151 · see citing works

5′‐( E )‐Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA–GalNAc Conjugates

Parmar, R. G., Willoughby, J. L. S., Liu, J., Foster, D. J., Brigham, B., Theile, C. S., Charissé, K., Akinc, A., Guidry, E. N., Pei, Y., et al. (2016) · ChemBioChem · doi:10.1002/cbic.201600130 · Cited by 143 · see citing works

Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation

Barbier‐Torres, L., Fortner, K. A., Iruzubieta, P., Delgado, T. C., Giddings, E. L., Chen, Y., Champagne, D., Fernández‐Ramos, D., Mestre, D., Gómez‐Santos, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16991-2 · Cited by 142 · see citing works

The Ashwell–Morell Receptor

Grewal, P. K. (2010) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(10)79013-3 · Cited by 136 · see citing works

Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis

Yu, J., Zhu, C., Wang, X., Kim, K., Bartolome, A., Dongiovanni, P., Yates, K. P., Valenti, L., Carrer, M., Sadowski, T., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe1692 · Cited by 132 · see citing works

Liver-Targeted Delivery of Oligonucleotides with N-Acetylgalactosamine Conjugation

Cui, H., Zhu, X., Li, S., Wang, P., & Fang, J. (2021) · ACS Omega · doi:10.1021/acsomega.1c01755 · Cited by 129 · see citing works

RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice

Yasuda, M., Gan, L., Chen, B., Kadirvel, S., Yu, C., Phillips, J. D., New, M. I., Liebow, A., Fitzgerald, K. J., Querbes, W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406228111 · Cited by 124 · see citing works

RNA interference: The molecular immune system

Bagasra, O., & Prilliman, K. R. (2004) · The Histochemical Journal · doi:10.1007/s10735-004-2192-8 · Cited by 123 · see citing works

The nano delivery systems and applications of mRNA

Li, M., Li, Y., Li, S., Jia, L., Wang, H., Li, M., Deng, J., Zhu, A., Ma, L., Li, W., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113910 · Cited by 123 · see citing works

Inhibition of HBV replication by siRNA in a stable HBV-producing cell line

Konishi, M., Wu, C. H., & Wu, G. Y. (2003) · Hepatology · doi:10.1002/hep.1840380410 · Cited by 119 · see citing works

PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2

Baum, M. A., Langman, C. B., Cochat, P., Lieske, J. C., Moochhala, S. H., Hamamoto, S., Satoh, H., Mourani, C. C., Ariceta, G., Torres, A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.07.025 · Cited by 119 · see citing works

The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of N-Acetylgalactosamine–Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human

McDougall, R., Ramsden, D., Agarwal, S., Agarwal, S., Aluri, K. C., Arciprete, M., Brown, C. R., Castellanos-Rizaldos, E., Charissé, K., Chong, S., et al. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000428 · Cited by 115 · see citing works

Preparation of cluster glycosides ofN-acetylgalactosamine that have subnanomolar binding constants towards the mammalian hepatic Gal/GalNAc-specific receptor

Lee, R. T., & Lee, Y. C. (1987) · Glycoconjugate Journal · doi:10.1007/bf01048365 · Cited by 110 · see citing works

Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference

Cornberg, M., Lok, A. S.-F., Terrault, N. A., & Zoulim, F. (2019) · Hepatology · doi:10.1002/hep.31030 · Cited by 109 · see citing works

Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials

Gane, E. J., Lim, Y., Kim, J. B., Jadhav, V., Shen, L., Bakardjiev, A. I., Huang, S. A., Cathcart, A. L., Lempp, F. A., Janas, M. M., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.023 · Cited by 102 · see citing works

From bench to bedside: Improving the clinical safety of GalNAc–siRNA conjugates using seed-pairing destabilization

Schlegel, M. K., Janas, M. M., Jiang, Y., Barry, J. D., Davis, W. P., Agarwal, S., Berman, D., Brown, C. R., Castoreno, A. B., LeBlanc, S., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac539 · Cited by 101 · see citing works

Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions

Kaffe, E., Roulis, M., Zhao, J., Qu, R., Sefik, E., Mirza, H., Zhou, J., Zheng, Y., Charkoftaki, G., Vasiliou, V., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.017 · Cited by 99 · see citing works

Liver biopsy findings from healthy potential living liver donors: Reasons for disqualification, silent diseases and correlation with liver injury tests

Minervini, M. I., Ruppert, K. M., Fontes, P., Volpes, R., Vizzini, G. B., de Vera, M. E., Gruttadauria, S., Miraglia, R., Pipitone, L., Marsh, J. W., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.030 · Cited by 95 · see citing works

The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells

Treré, D., FIUME, L., Giorgi, L. B. D., Stefano, G. D., Migaldi, M., & Derenzini, M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690708 · Cited by 95 · see citing works

Liver transplantation for hepatocellular carcinoma: evaluation of the alpha‐fetoprotein model in a multicenter cohort from Latin America

Piñero, F., Baña, M. T., de Ataíde, E. C., Duque, S. H., Marciano, S., Varón, A., Anders, M., Zerega, A. R., Menéndez, J., Zapata, R., et al. (2016) · Liver International · doi:10.1111/liv.13159 · Cited by 92 · see citing works

RNA interference as a novel treatment strategy for chronic hepatitis B infection

Hui, R. W., Mak, L., Seto, W., & Yuen, M. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0012 · Cited by 91 · see citing works

A New Era for Rare Genetic Diseases: Messenger RNA Therapy

Martini, P. G. V., & Guey, L. T. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.090 · Cited by 88 · see citing works

Asialoglycoprotein Receptor-Mediated Gene Delivery to Hepatocytes Using Galactosylated Polymers

Thapa, B., Kumar, P., Zeng, H., & Narain, R. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b00906 · Cited by 78 · see citing works

pH-Sensitive Nanomicelles for High-Efficiency siRNA Delivery in Vitro and in Vivo: An Insight into the Design of Polycations with Robust Cytosolic Release

Zhou, J., Wu, Y., Wang, C., Cheng, Q., Han, S., Wang, X., Zhang, J., Deng, L., Zhao, D., Du, L., et al. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b02915 · Cited by 78 · see citing works

2′-O-methylation at internal sites on mRNA promotes mRNA stability

Li, Y., Yang, Y., Gao, X., Wang, X., Zhao, D., Wang, R., Zhang, L., Gao, B., Zhang, Y., Zhang, L., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.04.011 · Cited by 74 · see citing works

Leading RNA interference therapeutics part 2: silencing delta-aminolevulinic acid synthase 1, with a focus on givosiran

de Paula Brandão, P. R., Titze-de-Almeida, S. S., & Titze-de-Almeida, R. (2020) · Molecular Diagnosis &amp; Therapy · doi:10.1007/s40291-019-00438-6 · Cited by 72 · see citing works

Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B

Pfefferkorn, M., Schott, T., Böhm, S. K., Deichsel, D., Felkel, C., Gerlich, W. H., Glebe, D., Wat, C., Pavlovic, V., Heyne, R., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.039 · Cited by 67 · see citing works

Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread

Ambike, S. S., Cheng, C., Feuerherd, M., Velkov, S., Baldassi, D., Afridi, S. Q., Porras-Gonzalez, D., Wei, X. C., Hagen, P., Kneidinger, N., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1248 · Cited by 66 · see citing works

Targeted delivery of oligonucleotides using multivalent protein–carbohydrate interactions

Kumar, V., & Turnbull, W. B. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00788f · Cited by 64 · see citing works

A siRNA targets and inhibits a broad range of SARS‐CoV‐2 infections including Delta variant

Chang, Y., Yang, C., Chen, Y., Yang, C., Chou, Y., Chou, H., Chang, T.-Y., Chao, T., Hsu, S., Ieong, S., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202115298 · Cited by 63 · see citing works

HBV Genome and Life Cycle

Wang, J., Huang, H., Liu, Y., Chen, R., Yan, Y., Shu, S., Xi, J., Zou, J., Yu, G., Feng, X., et al. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-9151-4_2 · Cited by 60 · see citing works

Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease

Wooddell, C. I., Blomenkamp, K., Peterson, R. M., Subbotin, V. M., Schwabe, C., Hamilton, J., Chu, Q., Christianson, D. R., Hegge, J., Kolbe, J., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.135348 · Cited by 59 · see citing works

Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease

Rider, D. A., Eisermann, M., Löffler, K., Aleku, M., Swerdlow, D. I., Dames, S., Hauptmann, J., Morrison, E., Lindholm, M., Schubert, S., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.029 · Cited by 59 · see citing works

Therapeutic RNA-silencing oligonucleotides in metabolic diseases

Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58 · see citing works

Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2

Singh, P. Y., Viehman, J. K., Mehta, R. A., Cogal, A. G., Hasadsri, L., Oglesbee, D., Olson, J. B., Seide, B. M., Sas, D. J., Harris, P. C., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab027 · Cited by 57 · see citing works

Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics – a Minireview

Jeon, J. Y., Ayyar, V. S., & Mitra, A. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03333-8 · Cited by 56 · see citing works

Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response

Kaur, R., Bramwell, V. W., Kirby, D. J., & Perrie, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.012 · Cited by 55 · see citing works

Review article: novel therapies for hepatitis B virus cure – advances and perspectives

Lin, C., & Kao, J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13694 · Cited by 52 · see citing works

Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans

Ayyar, V. S., Song, D., Zheng, S., Carpenter, T., & Heald, D. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000805 · Cited by 50 · see citing works

The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates

Zhang, L., Liang, Y., Liang, G., Tian, Z., Zhang, Y., Liu, Z., & Ji, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1090237 · Cited by 50 · see citing works

pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes

Hashiba, K., Sato, Y., & Harashima, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.046 · Cited by 49 · see citing works

Targeted delivery of siRNAs against hepatocellular carcinoma-related genes by a galactosylated polyaspartamide copolymer

Perrone, F. M., Craparo, E. F., Čemažar, M., Kamenšek, U., Drago, S. E., Dapas, B., Scaggiante, B., Zanconati, F., Bonazza, D., Grassi, M., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.020 · Cited by 49 · see citing works

PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum

Strøm, T. B., Tveten, K., & Leren, T. P. (2014) · Biochemical Journal · doi:10.1042/bj20130930 · Cited by 48 · see citing works

Enhancement of Stability and Activity of siRNA by Terminal Substitution with Serinol Nucleic Acid (SNA)

Kamiya, Y., Takai, J., Ito, H., Murayama, K., Kashida, H., & Asanuma, H. (2014) · ChemBioChem · doi:10.1002/cbic.201402369 · Cited by 45 · see citing works

Impact of stereopure chimeric backbone chemistries on the potency and durability of gene silencing by RNA interference

Liu, W., Iwamoto, N., Marappan, S., Luu, K., Tripathi, S., Purcell-Estabrook, E., Shelke, J. D., Shah, H., Lamattina, A., Pan, Q., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad268 · Cited by 44 · see citing works

Less Is More: Novel Hepatocyte-Targeted siRNA Conjugates for Treatment of Liver-Related Disorders

Weingärtner, A., Bethge, L., Weiss, L., Sternberger, M., & Lindholm, M. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.05.026 · Cited by 41 · see citing works

Chimeric siRNAs with chemically modified pentofuranose and hexopyranose nucleotides: altritol-nucleotide (ANA) containing GalNAc–siRNA conjugates: in vitro and in vivo RNAi activity and resistance to 5′-exonuclease

Kumar, P., Degaonkar, R., Guenther, D. C., Abramov, M., Schepers, G., Capobianco, M., Jiang, Y., Harp, J. M., Kaittanis, C., Janas, M. M., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa125 · Cited by 41 · see citing works

Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4)

Goldfarb, D. S., Lieske, J. C., Groothoff, J. W., Schalk, G., Russell, K., Yu, S., & Vrhnjak, B. (2023) · Urolithiasis · doi:10.1007/s00240-023-01453-3 · Cited by 41 · see citing works

In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors

Sasayama, Y., Hasegawa, M., Taguchi, E., Kubota, K., Kuboyama, T., Naoi, T., Yabuuchi, H., Shimai, N., Asano, M., Tokunaga, A., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.09.004 · Cited by 40 · see citing works

Metabolically Stable Anomeric Linkages Containing GalNAc–siRNA Conjugates: An Interplay among ASGPR, Glycosidase, and RISC Pathways

Pachamuthu, K., Mori, S., Matsuda, S., Erande, N. D., Datta, D., Willoughby, J. L. S., Taneja, N., O′Shea, J., Bisbe, A., Manoharan, R. M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01337 · Cited by 40 · see citing works

Paradigm shift in the treatment options of hepatocellular carcinoma

Su, T., Hsu, S., & Kao, J. (2021) · Liver International · doi:10.1111/liv.15052 · Cited by 39 · see citing works

Hepatocyte mARC1 promotes fatty liver disease

Lewis, L. C., Chen, L., Hameed, L. S., Kitchen, R. R., Maroteau, C., Nagarajan, S. R., Norlin, J., Daly, C. E., Szczerbinska, I., Hjuler, S. T., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100693 · Cited by 38 · see citing works

The three-component helicase/primase complex of herpes simplex virus-1

Bermek, O., & Williams, R. S. (2021) · Open Biology · doi:10.1098/rsob.210011 · Cited by 37 · see citing works

GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics

Thangamani, L., Balasubramanian, B., Easwaran, M., Natarajan, J., Pushparaj, K., Meyyazhagan, A., & Piramanayagam, S. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105864 · Cited by 35 · see citing works

Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection

Zai, W., Yang, M., Jiang, K., Guan, J., Wang, H., Hu, K.-Y., Huang, C., Chen, J.-L., Fu, W., Zhan, C.-Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01871-8 · Cited by 35 · see citing works

APOC3 siRNA and ASO therapy for dyslipidemia

Chebli, J., Larouche, M., & Gaudet, D. (2024) · Current Opinion in Endocrinology, Diabetes &amp; Obesity · doi:10.1097/med.0000000000000857 · Cited by 35 · see citing works

Emerging oral therapeutic strategies for inhibiting PCSK9

Ferri, N., & Marodin, G. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.11.003 · Cited by 35 · see citing works

SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1

Altamura, S., Schaeper, U., Dames, S., Löffler, K., Eisermann, M., Frauendorf, C., Müdder, K., Neves, J., & Muckenthaler, M. U. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000301 · Cited by 34 · see citing works

Engineering a biomimetic system for hepatocyte-specific RNAi treatment of non-alcoholic fatty liver disease

He, X., Chang, Z., Chen, F., Zhang, W., Sun, M., Shi, T., Liu, J., Chen, P., Zhang, K., Guan, S., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.10.038 · Cited by 32 · see citing works

Opportunities for innovation: Building on the success of lipid nanoparticle vaccines

Huang, J. Y., Yuen, D., Mintern, J. D., & Johnston, A. P. R. (2021) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2021.101468 · Cited by 31 · see citing works

Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection

Gupta, S. V., Fanget, M. C., MacLauchlin, C., Clausen, V. A., Li, J., Cloutier, D. J., Shen, L., Robbie, G. J., & Mogalian, E. (2021) · Drugs in R&D · doi:10.1007/s40268-021-00369-w · Cited by 30 · see citing works

Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis

Sutherland, J. E., Hettinger, J. L., Chan, A., Gilbert, J., Warner, G. L., & Davis, W. P. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0796 · Cited by 25 · see citing works

Advanced Strategies for Eliminating the cccDNA of HBV

Dong, J., Ying, J., Qiu, X., Lu, Y., & Zhang, M. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4842-1 · Cited by 24 · see citing works

Author Correction: The current landscape of nucleic acid therapeutics

Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00937-w · Cited by 23 · see citing works

Control of Hepatitis B Virus with Imdusiran, a Small Interfering RNA Therapeutic

Thi, E. P., Ye, X., Snead, N. M., Lee, A. C. H., Steuer, H. M. M., Ardzinski, A., Graves, I., Espiritu, C., Cuconati, A., Abbott, C., et al. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00514 · Cited by 23 · see citing works

Photodynamic augmentation of oncolytic virus therapy for central nervous system malignancies

Shimizu, K., Kahramanian, A., Jabbar, M. A. D. A., Demir, F. T., Gokyer, D., Uthamacumaran, A., Rajan, A. P., Saad, M. A., Gorham, J., Wakimoto, H., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216363 · Cited by 22 · see citing works

Reflections on Alnylam

Maraganore, J. M. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01304-3 · Cited by 21 · see citing works

Sinapine Improves LPS-Induced Oxidative Stress in Hepatocytes by Down-Regulating MCJ Protein Expression

Li, Y., Xu, Y., Tan, C. P., & Liu, Y. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120828 · Cited by 21 · see citing works

The Complex Role of HBeAg and Its Precursors in the Pathway to Hepatocellular Carcinoma

Padarath, K., Deroubaix, A., & Kramvis, A. (2023) · Viruses · doi:10.3390/v15040857 · Cited by 20 · see citing works

Current status of adult liver transplantation: utilization of living donor versus deceased donor graft

Tran, L. M., & Humar, A. (2021) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000849 · Cited by 20 · see citing works

Hyperoxalurie primitive

Cochat, P., Fargue, S., Bacchetta, J., Bertholet‐Thomas, A., Sabot, J.-F., & Harambat, J. (2011) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2011.03.004 · Cited by 19 · see citing works

Delivery of therapeutic small interfering RNA: The current patent-based landscape

Chen, Y., Xiong, S.-H., Li, F., Kong, X., Ouyang, D., Zheng, Y., Yu, H., & Hu, Y. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.06.011 · Cited by 19 · see citing works

Deleting the mitochondrial respiration negative regulator MCJ enhances the efficacy of CD8+ T cell adoptive therapies in pre-clinical studies

Wu, M.-H., Valença-Pereira, F., Cendali, F., Giddings, E. L., Pham-Danis, C., Yarnell, M. C., Novak, A. J., Brunetti, T. M., Thompson, S. B., Henao-Mejia, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48653-y · Cited by 19 · see citing works

Hepatitis B Gene Therapy Coming to Age.

Soriano, V. (2018) · PubMed · Cited by 16 · see citing works

Extrachromosomal DNA (ecDNA): Unveiling its role in cancer progression and implications for early detection

Wu, S., Tao, T., Zhang, L., Zhu, X. M., & Zhou, X. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21327 · Cited by 15 · see citing works

Novel therapeutic approaches based on the pathological role of gut dysbiosis on the link between nonalcoholic fatty liver disease and insulin resistance.

Bellucci, E., Chiereghin, F., Pacifici, F., Donadel, G., Stefano, A. D., Malatesta, G., Valente, M. G., Guadagni, F., Infante, M., Rovella, V., et al. (2023) · PubMed · doi:10.26355/eurrev_202303_31558 · Cited by 14 · see citing works

Prolonged cultured human hepatocytes as an in vitro experimental system for the evaluation of potency and duration of activity of RNA therapeutics: Demonstration of prolonged duration of gene silencing effects of a GalNAc-conjugated human hypoxanthine phosphoribosyl transferase (HPRT1) siRNA

Yang, Q., Humphreys, S. C., Lade, J. M., & Li, A. P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114374 · Cited by 13 · see citing works

Liver cancer cells as the model for developing liver-targeted RNAi therapeutics

Hou, B., Qin, L., & Huang, L. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.01.007 · Cited by 12 · see citing works

Application of improved GalNAc conjugation in development of cost-effective siRNA therapies targeting cardiovascular diseases

Li, Q., Yin, K., Ma, H., Liu, H.-H., Li, S., Luo, X., Hu, R., Zhang, W., Lv, Z.-S., Niu, X.-L., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.008 · Cited by 11 · see citing works

RNA interference rebooted

Hayden, E. C. (2014) · Nature · doi:10.1038/508443a · Cited by 10 · see citing works

Morindone as a potential therapeutic compound targeting TP53 and KRAS mutations in colorectal cancer cells

Chee, C. W., Hashim, N. M., & Rashid, N. N. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.110928 · Cited by 9 · see citing works

Analysis of the pharmacokinetics and efficacy of RBD1016 – A GalNAc-siRNA targeting Hepatitis B Virus X gene using semi-mechanistic PK/PD model

Li, Q., Geng, T., Li, H., Zheng, S., Svedlund, S., Gan, L., Egnell, A., Gao, S., Chen, R., & Hu, P. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e31924 · Cited by 8 · see citing works

Safety and antiviral activity of RBD1016, a RNAi therapeutic, in Chinese subjects with chronic hepatitis B virus (HBV) infection

Seto, W., Liang, Z., Gan, L., Fu, J., & Yuen, M. (2023) · Journal of Hepatology · doi:10.1016/s0168-8278(23)03287-7 · Cited by 8 · see citing works

Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection

Yuen, M., Heo, J., Nahass, R., Wong, G. L., Burda, T., Bhamidimarri, K. R., Hu, T., Nguyen, T., Lim, Y., Chen, C.-Y., et al. (2023) · Journal of Hepatology · doi:10.1016/s0168-8278(23)00618-9 · Cited by 8 · see citing works

Asiaticoside conveys an antifibrotic effect by inhibiting activation of hepatic stellate cells via the Jagged-1/Notch-1 pathway

Xiao, X., & Zhang, Q. (2022) · Journal of Natural Medicines · doi:10.1007/s11418-022-01653-y · Cited by 7 · see citing works

eEF1A2 siRNA Suppresses MPP+-Induced Activation of Akt and mTOR and Potentiates Caspase-3 Activation in a Parkinson’s Disease Model

Khwanraj, K., Prommahom, A., & Dharmasaroja, P. (2023) · The Scientific World JOURNAL · doi:10.1155/2023/1335201 · Cited by 7 · see citing works

Improving the care of high-risk patients: The potential of PCSK9

Stock, J. K. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.11.050 · Cited by 6 · see citing works

Jag1 insufficiency alters liver fibrosis via T cell and hepatocyte differentiation defects

Mašek, J., Filipovic, I., Hul, N. V., Belicová, L., Jiroušková, M., Oliveira, D. V., Frontino, A. M., Hankeová, S., He, J., Turetti, F., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00145-8 · Cited by 6 · see citing works

Polyethyleneimine-mediated assembly of DNA nanotubes for KRAS siRNA delivery in lung adenocarcinoma therapy

Bai, J.-H., Yu, Q.-T., Wang, Y., Chen, C., Ma, L., Yuan, Y., Gan, Y.-J., Yang, J., Zhu, S., Ran, Y.-H., et al. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00791c · Cited by 5 · see citing works

Safety, pharmacokinetics, and antiviral activity of single ascending doses of ALG-125755, a GalNAc-conjugated small interfering RNA, in subjects with chronic hepatitis B

Jucov, A., Gane, E. J., Fitzgerald, M., Le, K. N., Wang, S., Ammar, L., Burnett, C., Haceatrean, A., Gupta, K., Clark, D., et al. (2023) · Journal of Hepatology · doi:10.1016/s0168-8278(23)03303-2 · Cited by 5 · see citing works

Promising novel siRNA for the treatment of hypertension

Fernández-Ruíz, I. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00916-9 · Cited by 5 · see citing works

Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA+ chronic hepatitis B patients

Ganchua, S. C., Paratala, B., Iott, C. L., Yuen, M., Gane, E. J., Eley, T., Sims, K., Gray, K., Antoniello, D., Lam, A. M. I., et al. (2022) · Journal of Hepatology · doi:10.1016/s0168-8278(22)01998-5 · Cited by 4 · see citing works

RBD1016-a novel anti-HBV GalNAc-siRNA drug resulted in sustained HBsAg reduction and seroconversion in mice models

Gan, L., Zheng, S., Li, F., Guo, Z., Yu, H., Zhang, H., Liang, Z., & Gao, S. (2023) · Journal of Hepatology · doi:10.1016/s0168-8278(23)03092-1 · Cited by 4 · see citing works

Metabolite Identification and Quantitation of RBD1016 siRNA: A Direct Comparison of Hybridization-Based LC-FD and LC-HRAM Assays

Ji, Y., Guo, Z., Yan, M., Chu, L., Meng, M., Chu, Y., Yu, H., & Wang, L. (2023) · Bioanalysis · doi:10.4155/bio-2023-0161 · Cited by 4 · see citing works

Continued suppression of viral markers observed following discontinuation of nucleos (t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729

Yuen, M., Strasser, S. I., Sukeepaisarnjaroen, W., Sharma, V., Antoniello, D., Medvedeva, E. L., Thi, E. P., Picchio, G., Eley, T., & Sims, K. (2022) · Journal of Hepatology · doi:10.1016/s0168-8278(22)02050-5 · Cited by 4 · see citing works

Novel diamine-scaffold based N -acetylgalactosamine (GalNAc)–siRNA conjugate: synthesis and in vivo activities

Li, Q., Dong, M., & Chen, P. (2024) · RSC Advances · doi:10.1039/d4ra03023k · Cited by 3 · see citing works

9th Annual Meeting of the Oligonucleotide Therapeutics Society

Brett P. Monia, O. B. O. T. B. O. T. O. T. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.1505 · Cited by 3 · see citing works

The HBV siRNA, ALG-125755, demonstrates a favourable nonclinical profile and significant and durable hepatitis B surface antigen reductions in the AAV-HBV mouse efficacy model

Fitzgerald, M., Gupta, K., Le, K. N., Mukherjee, S., Hong, J., Nguyen, K., Chen, A., Rajwanshi, V. K., Williams, C., Venkatraman, M., et al. (2022) · Journal of Hepatology · doi:10.1016/s0168-8278(22)01988-2 · Cited by 3 · see citing works

[Structure and function of glycoconjugates on erythrocyte membrane].

Iwamori, M. (1988) · PubMed · Cited by 1 · see citing works

[Structure and function of glycoconjugates involved in dengue virus infection].

Hidari, K. I. P. J., & Suzuki, T. (2010) · PubMed · Cited by 1 · see citing works

Pharmacodynamic durability of ALG-125755, a GalNAc-conjugated siRNA, correlated with total and RNA induced complex (RISC) bound siRNA in mouse liver

Gupta, K., Fitzgerald, M., Hong, J., Kao, C. C., Liu, C., Le, K. N., Mukherjee, S., Misner, D., Venkatraman, M., McClure, M., et al. (2023) · Journal of Hepatology · doi:10.1016/s0168-8278(23)03113-6 · Cited by 1 · see citing works

KYLO-0603, a novel liver-targeting, thyroid hormone receptor-β agonist for the inhibition of MASH progression

Lu, X., Wang, S., Du, Y., Xie, B., Chen, Q., Lin, J., Chen, B., & Cui, K. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331768 · Cited by 30 · see citing works

Nanoparticles Used for the Delivery of RNAi-Based Therapeutics

Ren, T., Ma, L., Fu, P., & Zhang, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111502 · Cited by 29 · see citing works

Metastatic breast cancer cells are vulnerable to fatty acid oxidation inhibition through DDX3-DRP1-mediated mitochondrial plasticity

Hsu, W.-J., Hsu, M.-C., Chu, C., Lee, Y., Yang, C.-C., Liu, Z., Lee, C., Lin, Y.-S., & Lin, C. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103845 · Cited by 12 · see citing works

A non-apoptotic caspase-8–meteorin pathway in hepatocytes promotes MASH fibrosis

Wang, X., Moore, M. P., Shi, H., Xiao, Y., Zhang, J., Faccioli, L. A. P., Hu, Z., Khalid, S., Saleheen, D., Stupack, D. G., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01355-1 · Cited by 11 · see citing works

Emerging nano-immunotherapeutic strategies achieve metastatic colorectal cancer precision therapy

Jiang, S., Zhang, Z., Mao, Y., Xia, X., Luo, J., Zhang, Y., & Yuan, Y. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03933-7 · Cited by 11 · see citing works

Hepatic IκBζ promotes alcohol-associated liver disease and acute hepatitis by enhancing CXCL1-Mediated neutrophil infiltration

Liu, L., Qian, S., Li, W., Dong, S., Ya, R., He, Y., Huang, H., Chen, Y., Ma, N., Hao, Y., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.06.022 · Cited by 9 · see citing works

Emergence of Small Nucleic Acids as Drugs in Precision Medicine

Cheng, X., Wang, Y., Zhang, T., Cao, Y., Cheng, H., Du, Y., Ge, X., Ren, B., Lu, J. G., & Li, L. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3678 · Cited by 8 · see citing works

Liver targeted nanomedicine for treatment of fibrosis and hepatocellular carcinoma: Emerging strategies in ligand-guided, stimuli-responsive and gene-based delivery

Sahu, P., & Satapathy, T. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107935 · Cited by 6 · see citing works

Research progress and development strategies of antibody-oligonucleotide conjugates

Fan, W., Luan, W., Yu, W., Li, Y., Wei, C., Liu, X., Ni, L., Cao, H., Fang, C., & Fu, Y. (2026) · Gene Therapy · doi:10.1038/s41434-026-00621-5 · Cited by 6 · see citing works

Nanomaterial-enabled RNA therapeutics: bridging delivery barriers to clinical translation

Pandey, K., Jha, S., Chaliha, L. B., Gosai, H. B., & Patel, R. (2026) · Frontiers in Nanotechnology · doi:10.3389/fnano.2026.1860221 · Cited by 6 · see citing works

Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management

Satyam, S. M., El-Tanani, M., Patni, M. A., Rehman, A., Irshad, S. M., Raheem, R., Junais, E., John, A. A., Rassal, R. Y., Kumari, R., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05515-3 · Cited by 5 · see citing works

Betaine-homocysteine methyltransferase protects against acetaminophen-induced acute liver failure via BACH1-SCD1-oleic acid axis

Zhang, Y., Yang, X.-M., Jin, Q., Chen, J.-Y., Zhu, N.-B., Ju, Y., Lin, Z., Yang, Z., Dong, Y.-N., Li, C., et al. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01622-7 · Cited by 5 · see citing works

Nanoparticle-mediated liver targeted delivery of IFN-γ confers enhanced anti-fibrotic efficacy with reduced systemic toxicity

Yang, J., Zhu, L., Zhao, H., Huang, J., Ying, S., Zhu, J., Yan, Y., & Zhu, Y. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148277 · Cited by 5 · see citing works

Tissue‐specific gene delivery approaches

Nasr, S. S., Cheema, Y., Stern, A., Tabah, O., Poore, S., & Duncan, G. A. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70125 · Cited by 3 · see citing works

GalNAc-modified five-component lipid nanoparticles for liver-targeted delivery of p65 siRNA to alleviate cytokine storm in liver injury via NF-κB targeting

Liang, Z., Li, S., Huang, H., Luo, S., Jiang, H., Luo, L., Li, J., & Zhao, K. (2026) · Journal of Materials Chemistry B · doi:10.1039/d6tb00003g · Cited by 3 · see citing works

Programmable Aptamer-Embedded Circular RNAs for Targeted Antigen-Presenting Cells ImmunotherapyPreprint

Zhang, Y., Wang, W., Qian, X., Chen, J., Ding, D., Gan, S., Yi, W., Li, Y., Deng, Y., Chen, Z., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.28.679023 · Cited by 3 · see citing works

Organ‐Targeted and Organelle‐Targeted Liposome Gene Vector Construction

Wang, Q., Xiong, S., Zhao, R., Chen, J., Li, S., Jiang, W., & Zhang, L. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202502254 · Cited by 2 · see citing works

Silencing of lncRNA HOTAIR Using Eyedrops as a Potential Treatment for Diabetes-Associated Retinal Dysregulation and Dysfunction

Wang, E., Feng, B., Chen, S., Wang, H., Ling, T., & Chakrabarti, S. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.1.24 · Cited by 2 · see citing works

Beyond inflammation: siRNA strategies for precision targeting in rheumatological disorders

El‐Sehrawy, A. A. M. A., Mahmood, S. H., Jawad, M. J., Sanghvi, G. V., Uthirapathy, S., Roopashree, R., Kashyap, A., Sabarivani, A., Ray, S., & kareem, M. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04959-2 · Cited by 1 · see citing works

Dual targeted gene delivery strategy mediated by GalNAc-modified lipid nanoparticles enhances liver regeneration through specific knockdown of MKK4

Zhai, X., Xing, J., Hou, L., Zhang, T.-R., He, W., Gan, L., Zhou, S.-Y., & Zhang, B. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103059 · Cited by 1 · see citing works

Hepatocyte-Targeted Cyclic Peptide LYTACs for PCSK9 Degradation and LDL Cholesterol Metabolic Regulation

Feng, B., Shi, Y., Xu, J., Hu, M., Liang, S., Li, Y., & Gan, W. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00029 · Cited by 1 · see citing works

Oroxylin A ameliorates hepatic steatosis and non-alcoholic fatty liver disease through the regulation of CPT1A m6A methylation in hepatocytes

Yihong, J., Gu, H., Wang, M., Miao, Y., Gao, C., Zhang, J., & Luo, L. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102598 · Cited by 1 · see citing works

RNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside

Ali, I., Qiu, J., Cheang, W. S., Wang, G., & Xu, S. (2026) · Research · doi:10.34133/research.1288 · Cited by 1 · see citing works

Emerging Approaches for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease: The Application of Nanomedicines

Shi, T., Yue, H., Wang, W., Gao, Y., Xu, S., Gao, J., & Yin, C. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s603396 · Cited by 1 · see citing works

The Crosstalk Between Non-Coding RNAs and Lipid Metabolism in Chronic Disease Progression

Zayani, Z., Matinahmadi, A., Tavakolpournegari, A., Moosavi, S. S., & Bidooki, S. H. (2025) · Lipidology · doi:10.3390/lipidology2040019

The role of siRNA and Argonaute 2 in Cancer Therapy: Molecular mechanisms and drug design perspectives

Uddin, M. S., Faisal, M. R., Hossain, A. A., Hossain, A. A., Bristy, N. J., Fatama, M. U., Koko, M. A. R., & Islam, T. (2025) · World Journal of Biology Pharmacy and Health Sciences · doi:10.30574/wjbphs.2025.24.2.0971

The Computational Journey of siRNA Silencing Efficiency: Resources, Methods, and Future Directions

Ren, L., Li, H., Zhang, Y., Luo, N., & Zhang, Y. (2026) · Current Drug Targets · doi:10.2174/0113894501438507251212062604

LAMC3 promotes the development of prostate cancer via modulating the cell cycle progression

Chen, L., Chen, Z., Ding, H.-K., Ge, Q., Xu, L., Zhou, J., Wang, H., & Liang, C. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116544

MicroRNA clusters as regulators in progressive fatty liver disease Spectrum: from mechanistic insights to therapeutic opportunities

Karunakara, S. H., & Santhekadur, P. K. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153846

Engineering the Future of Precision Medicine: A Comprehensive Guide to RNA Therapeutics

Athanasopoulou, K., Daneva, G. N., Michalopoulou, V.-I., Stamelou, M.-L., Tsiakanikas, P., & Adamopoulos, P. G. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48080809

Engineering Polymeric Vectors for Nucleic Acid Delivery: Linking Molecular Architecture, Biological Function, and Computational Design

Arikibe, J. E., Mazzetta, A. M., Casagrande, L., de Cotret, A. R., Tomlinson, C., Gris, D., & Caliceti, P. (2026) · Open Research Europe · doi:10.12688/openreseurope.24908.1

Oligonucleotide and RNA-targeted therapeutics for chronic hepatitis B: Antigen reduction, delivery, and functional cure strategies

Meng, X., Mahmood, F., Li, H., & 周太成 (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103125

Liver-targeted DGAT2 siRNA ameliorates steatosis and fibrosis in a high-fat diet–induced MASH mouse model

Zhang, E., Zheng, W., LI, Y., Cheng, Z., Cai, Y., Cheng, Y., Zhang, X., Hou, Q., Liu, Y., Bingxue, M., et al. (2026) · Journal of drug targeting · doi:10.1080/1061186x.2026.2721709

Hepatitis B surface antigen-targeting strategies for clearance: A review of progress from mechanistic exploration to clinical translation

Wang, L. (2026) · World Journal of Hepatology · doi:10.4254/wjh.125343

GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics

Springer, A. D., & Dowdy, S. F. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0736 · Cited by 711 · see citing works

GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics

Thangamani, L., Balasubramanian, B., Easwaran, M., Natarajan, J., Pushparaj, K., Meyyazhagan, A., & Piramanayagam, S. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105864 · Cited by 35 · see citing works

Multivalent <i>N</i> -Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing

Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141 · see citing works

Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug

Debacker, A. J., Voutila, J., Catley, M. C., Blakey, D. C., & Habib, N. A. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.015 · Cited by 403 · see citing works

The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates

Zhang, L., Liang, Y., Liang, G., Tian, Z., Zhang, Y., Liu, Z., & Ji, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1090237 · Cited by 50 · see citing works